TKNO

Alpha Teknova, Inc. is a producer of critical reagents for the research, discovery, development, and commercialization of therapies, vaccines, and molecular diagnostics. It offers two primary product categories, which include lab essentials and clinical solutions. It also offers three primary product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. The Company offers its liquid cell culture media and supplements and molecular biology reagents in both of its two product categories; pre-poured media plates are available in its Lab Essentials category only. It supports customers spanning the life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and others, with catalog and custom, made-to-order products.

Wall Street analysts forecast TKNO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TKNO is 7.00 USD with a low forecast of 7.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Alpha Teknova Inc revenue for the last quarter amounts to 10.45M USD, increased 9.17 % YoY.

Alpha Teknova Inc. EPS for the last quarter amounts to -0.08 USD, decreased -46.67 % YoY.

Alpha Teknova Inc (TKNO) has 173 emplpoyees as of December 16 2025.

Today TKNO has the market capitalization of 245.70M USD.